No Data
New Analysis of Omeros' Narsoplimab to Treat Complications From Stem Cell Transplant Support Results
Omeros Analyst Ratings
Omeros Announces Update on Statistical Analysis of Narsoplimab Primary Endpoint
Meros Announces Sensitivity Results For Narsoplimab In TA-TMA Patients, Confirming Over 3-Fold Mortality Risk Reduction; Primary Endpoint Met. BLA Resubmission To FDA This Quarter, MAA Submission In Europe By Mid-Year.
Express News | Omeros Corp - Plans to Resubmit to FDA Later This Quarter Bla for Narsoplimab
Express News | Omeros Corp: Sensitivity Analyses Support Results of Primary Endpoint Analysis
